The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Characterizing high-risk multiple myeloma and barriers that remain for these patients
Eileen Boyle, MD, PhD, University College London, London, UK, discusses the diagnosis and management of patients with high-risk multiple myeloma. High-risk patients are characterized by both intrinsic and extrinsic tumor features, involving T-cells, NK-cells, and stromal cells. Identifying high-risk patients at diagnosis remains challenging, and Dr Boyle emphasizes the need for more clinical trials focused on these patients. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
